多西他赛+表阿霉素方案在乳腺癌新辅助化疗中的应用

摘要

目的：探讨多西他赛联合表阿霉素方案在乳腺癌新辅助化疗中的应用价值。方法：2013年7月10日-2014年1月10日收治局部进展期乳腺癌患者80例，对其临床资料进行回顾性分析。结果：80例患者接受治疗后临床总有效率93.75%，完全缓解26例，部分缓解49例，稳定5例，进展0。结论：替多西他赛+表阿霉素方案在乳腺癌新辅助化疗中具有重要的应用价值，值得临床大力推广。%Objective:To explore the application value of docetaxel combined with epirubicin scheme in neoadjuvant chemotherapy of breast carcinoma.Methods:80 patients with locally advanced breast cancer were selected from 10 July 2013 to 10 January 2014,and their clinical data were retrospectively analyzed.Results:After treatment,the total clinical effective rate in those 80 patients was 93.75% ;26 cases were completed remission;49 cases were partial remission;5 cases were stable;no case progressed.Conclusion:The scheme of combing docetaxel with epirubicin has important application value on the treatment of neoadjuvant chemotherapy in breast carcinoma,so it is worthy of clinical popularization.